Juno Therapeutics, Inc.

No Longer Reporting

The company has not filed an annual or quarterly report since its FY2017 10-K, filed Mar 1, 2018. Its latest SEC filing is a SC 13G/A from Feb 14, 2019.

The sections below describe the company as of the FY2017 annual report.

What Did They Do?

Develops cell-based cancer immunotherapies for patients with blood cancers and solid tumors.

How Did They Make Money?

Juno receives collaboration fees and reimbursement for development costs, plus royalties tied to sales of CD19 candidates in Celgene's territory; sublicense arrangements also generate revenue.

FY2017 revenue

Who Were Their Customers?

Juno works with commercial collaborators including Celgene, Editas, Fate and MedImmune on product development, manufacturing and commercialization, and also earns revenue from sublicense arrangements.

Did Revenues Turn Into Profits?

No. It lost $437.1M in FY2017.

Operating income, FY2017

−400% of revenue

▲ +75% (Loss) vs FY2016 (−$255.6M, −322%)

Net income, FY2017

−391% of revenue

▲ +78% (Loss) vs FY2016 (−$245.6M, −309%)

Free cash flow, FY2017

−256% of revenue

▲ +16% (Loss) vs FY2016 (−$246.1M, −310%)

How Were They Changing?

Since the FY2017 annual report

Mar 6, 2018 Celgene completed its acquisition of Juno Juno became a wholly owned Celgene subsidiary and requested Nasdaq delisting.

Who Did They Compete With?

Competes with Novartis, Kite, Gilead Sciences, Amgen, Cellectis, Pfizer, Servier, Johnson & Johnson, Transposagen Biopharmaceuticals, Legend Biotech, Poseida, bluebird bio, Bellicum, Celyad, NantKwest, Intrexon, ZIOPHARM, Unum Therapeutics, Adaptimmune, and GlaxoSmithKline

Comments